Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Psoriasis

Psoriasis

Recruiting

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Status
Recruiting
Principal Investigator
Sunil Kalia
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

The purpose of this study is to evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis who have had an inadequate response to their current biologic agent regimen.

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis

The  purpose of this study is to understand the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in a psoriasis study involving BMS-986165. 

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Closed for Recruitment

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

To assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis. To compare the proportion of subjects with moderate to severe psoriasis is experiencing a 75% improvement as measured by reduction in psoriasis area and severity index (PASI-75) score after 12 weeks of treatment between doses of BMS-986165 and placebo.  

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18-70

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

The purpose of this study is to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 24, to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with or without loading regimen in subjects with active Psoriatic Arthritis (PsA) despite current or previous NSAID, DMARD therapy and/or previous anti-TNFα therapy.

Status
Closed for Recruitment
Principal Investigator
Jan Dutz
Body Locations and Systems
Psoriasis
Psoriatic Arthritis
Area
Vancouver
Age
18 and above

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18-99

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Status
Closed for Recruitment
Principal Investigator
Youwen Zhou
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

This is an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. Subjects on secukinumab at the end of treatment period in phase III studies (e.g., ongoing CAIN457A2302 and CAIN457A2303 and potentially other secukinumab phase III studies) will be eligible to join this extension study.

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Chronic Plaque Psoriasis (Ps) Registry

The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18-99

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs.

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18-99
Subscribe to Psoriasis

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy